EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats

Stijn J M Niessen iD, Hans S Kooistra, Yaiza Forcada, Charlotte R Bjørnvad iD, Balazs Albrecht iD, Franziska Roessner, Esther Herberich, Carla Kroh

Journal of Veterinary Internal Medicine · 2024-07-01 · 38 (4) · 2099-2119

DOI: 10.1111/jvim.17124 ↗

At a glance

Journal article in Journal of Veterinary Internal Medicine, published online on 2024-07-01. Written by Stijn J M Niessen and 7 co-authors. Institution: Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands. Major MEDLINE topics: Cat Diseases, Hypoglycemic Agents, Insulin, Sodium-Glucose Transporter 2 Inhibitors. Cited 23 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Boehringer Ingelheim Animal Health.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Options for treatment of diabetes mellitus in cats are limited to insulin injections and monitoring for hypoglycemia. Hypothesis Once daily sodium-glucose cotransporter-2 inhibitor velagliflozin PO is noninferior to insulin injections. Animals Client-owned diabetic cats (127 safety; 116 efficacy assessment).

Methods

Prospective, randomized (1 mg/kg velagliflozin), positive controlled (titrated Caninsulin), open label, noninferiority field trial, comparing number of cats with treatment success in ≥1 clinical variable and ≥1 glycemic variable (margin Δ: 15%) on Day 45; secondary endpoints included glycemic and clinical assessments during 91 days.

Results

On Day 45, 29/54 (54%) velagliflozin-treated cats and 26/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority (difference −11.8%; upper 1-sided 97.5% confidence interval, −∞ to 6.3%). By Day 91, quality of life (QoL), polyuria, and polydipsia had improved in 81%, 54% and 61% (velagliflozin); on blood glucose (BG) curves, mean BG was <252 mg/dL in 42/54 (78%; velagliflozin) and 37/62 (60%; Caninsulin); minimum BG was <162 mg/dL in 41/54 (76%; velagliflozin) and 41/62 (66%; Caninsulin); serum fructosamine was <450 μmol/L in 41/54 (76%; velagliflozin) and 38/62 (61%; Caninsulin). Velagliflozin's most frequent adverse events were loose feces/diarrhea (n = 23/61, 38%), positive urine culture (n = 19/61, 31%), and nonclinical hypoglycemia (BG <63 mg/dL; n = 8/61, 13%); Caninsulin's: clinical and nonclinical hypoglycemia (n = 35/66, 53%), positive urine culture (n = 18/66, 27%), and loose feces/diarrhea (n = 10/66, 15%). Diabetic ketoacidosis occurred in 4/61 (7%; velagliflozin) and 0/66 (Caninsulin). Conclusions and Clinical Importance Once daily oral administration of velagliflozin was noninferior to insulin injections, showed good QoL and glycemia without clinical hypoglycemia.

Subjects

MeSH terms (MEDLINE)

Cat DiseasesHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 InhibitorsAnimalsCatsFemaleMaleAdministration, OralBlood GlucoseDiabetes MellitusDrug Administration ScheduleProspective Studies

Author keywords

antidiabeticbeta‐cellcompliancefeline diabetes mellitusglucosuriaglucotoxicityglycemic controlprospective clinical trialsodium‐glucose cotransporter‐2 (SGLT2) inhibitor

Substances

Blood GlucoseHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 Inhibitors

Authors and institutions

  • Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands.
  • Royal Veterinary College, University of London, Hertfordshire, United Kingdom.
  • Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
  • Bjørnvad Consultancy, Vedbæk, Denmark.
  • Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.

ORCID profiles: Stijn J M Niessen, Charlotte R Bjørnvad, Balazs Albrecht

Funding

  • Boehringer Ingelheim Animal Health

Cite

APA

Niessen, S. J. M., Kooistra, H. S., Forcada, Y., Bjørnvad, C. R., Albrecht, B., Roessner, F., Herberich, E., & Kroh, C. (2024). Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats. Journal of Veterinary Internal Medicine, 38(4), 2099-2119. https://doi.org/10.1111/jvim.17124

Vancouver

Niessen SJM, Kooistra HS, Forcada Y, Bjørnvad CR, Albrecht B, Roessner F, et al. Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats. Journal of Veterinary Internal Medicine. 2024;38(4):2099-2119. doi:10.1111/jvim.17124

BibTeX
@article{Niessen2024,
  author = {Niessen, Stijn J M and Kooistra, Hans S and Forcada, Yaiza and Bjørnvad, Charlotte R and Albrecht, Balazs and Roessner, Franziska and Herberich, Esther and Kroh, Carla},
  title = {Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2024},
  volume = {38},
  number = {4},
  pages = {2099--2119},
  doi = {10.1111/jvim.17124}
}
Start for free →